[HTML][HTML] Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations …

B Fischer, T Robinson, C Bullen, V Curran… - International Journal of …, 2022 - Elsevier
Background Cannabis use is common, especially among young people, and is associated
with risks for various health harms. Some jurisdictions have recently moved to …

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

JC Arnold, D McCartney, A Suraev… - Clinical and …, 2023 - Wiley Online Library
Global interest in the non‐intoxicating cannabis constituent, cannabidiol (CBD), is
increasing with claims of therapeutic effects across a diversity of health conditions. At …

[HTML][HTML] Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process

A Bhaskar, A Bell, M Boivin, W Briques… - Journal of cannabis …, 2021 - Springer
Background Globally, medical cannabis legalization has increased in recent years and
medical cannabis is commonly used to treat chronic pain. However, there are few …

The potential of cannabidiol in the COVID‐19 pandemic

G Esposito, M Pesce, L Seguella… - British journal of …, 2020 - Wiley Online Library
Identifying drugs effective in the new coronavirus disease 2019 (COVID‐19) is crucial,
pending a vaccine against SARS‐CoV2. We suggest the hypothesis that cannabidiol (CBD) …

[HTML][HTML] Access to cannabidiol without a prescription: a cross-country comparison and analysis

IS McGregor, EA Cairns, S Abelev, R Cohen… - International Journal of …, 2020 - Elsevier
Background Recent legislative change has allowed increased access to cannabis products
in many jurisdictions. In some locations, this includes over-the-counter (OTC) and/or online …

Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: a comprehensive review

K Singh, B Bhushan, DK Chanchal… - Behavioural …, 2023 - Wiley Online Library
Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its
potential therapeutic applications. This thorough analysis explores the increasing …

Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD)

J Hardy, R Greer, G Huggett, A Kearney… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To determine whether cannabidiol (CBD) oil can improve symptom distress in
patients with advanced cancer receiving palliative care. METHODS Participants were adults …

Delivering therapeutic cannabinoids via skin: Current state and future perspectives

AO Tijani, D Thakur, D Mishra, D Frempong… - Journal of Controlled …, 2021 - Elsevier
Adequate evidence exists in the literature indicating a relatively positive shift with regards to
the legal acceptance of cannabis and cannabis-derived products for medicinal purposes in …

[HTML][HTML] Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?

DW Lachenmeier, S Habel, B Fischer, F Herbi… - …, 2019 - ncbi.nlm.nih.gov
Cannabidiol (CBD)-containing products are widely marketed as over the counter products,
mostly as food supplements. Adverse effects reported in anecdotal consumer reports or …

[HTML][HTML] A systematic review of cannabidiol trials in neurodevelopmental disorders

NF Parrella, AT Hill, PG Enticott, P Barhoun… - Pharmacology …, 2023 - Elsevier
Cannabis-derived compounds, such as cannabidiol (CBD) and delta-9-trans-
tetrahydrocannabinol (THC), are increasingly prescribed for a range of clinical indications …